Open Access

Clinical, histological, immunohistochemical and genetic factors associated with measurable response of high‑risk canine mast cell tumours to tyrosine kinase inhibitors

  • Authors:
    • Rodrigo dos Santos Horta
    • Antonio Giuliano
    • Gleidice Eunice Lavalle
    • Mariana de Pádua Costa
    • Roberto Baracat de Araújo
    • Fernando Constantino‑Casas
    • Jane Margaret Dobson
  • View Affiliations

  • Published online on: November 1, 2017     https://doi.org/10.3892/ol.2017.7323
  • Pages:129-136
  • Copyright: © Horta et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: HTML 0 views | PDF 0 views
0

Abstract

The aim of the present prospective-retrospective study was to evaluate the response of high‑risk canine mast cell tumours (MCTs) to tyrosine kinase inhibitors (TKIs) and to correlate this with prognostic factors. A total of 24 dogs presented with macroscopic cutaneous MCTs at disease stage II or III, and therefore, at high‑risk of associated mortality, were included in the study and treated with masitinib (n=20) or toceranib (n=4). A total of 12/24 dogs achieved an objective response and the overall survival (OS) for all subjects was 113 days. Dogs responding to treatment had a significant increase in OS compared to non‑responders (146.5 days vs. 47 days, P=0.02). Internal tandem duplications in exon 11 of the c‑kit gene were identified in 6/24 cases. Ki67, KIT immunolabelling and c‑kit mutation did not provide information regarding prognosis or prediction of response to TKIs in this population. Initial response to TKIs appears to be the most reliable prognostic factor for survival duration.

Related Articles

Journal Cover

January 2018
Volume 15 Issue 1

Print ISSN: 1792-1074
Online ISSN:1792-1082

2016 Impact Factor: 1.39
Ranked #68/217 Oncology
(total number of cites)

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Horta, R.d., Giuliano, A., Lavalle, G.E., Costa, M.d., de Araújo, R.B., Constantino‑Casas, F., & Dobson, J.M. (2018). Clinical, histological, immunohistochemical and genetic factors associated with measurable response of high‑risk canine mast cell tumours to tyrosine kinase inhibitors. Oncology Letters, 15, 129-136. https://doi.org/10.3892/ol.2017.7323
MLA
Horta, R. d., Giuliano, A., Lavalle, G. E., Costa, M. d., de Araújo, R. B., Constantino‑Casas, F., Dobson, J. M."Clinical, histological, immunohistochemical and genetic factors associated with measurable response of high‑risk canine mast cell tumours to tyrosine kinase inhibitors". Oncology Letters 15.1 (2018): 129-136.
Chicago
Horta, R. d., Giuliano, A., Lavalle, G. E., Costa, M. d., de Araújo, R. B., Constantino‑Casas, F., Dobson, J. M."Clinical, histological, immunohistochemical and genetic factors associated with measurable response of high‑risk canine mast cell tumours to tyrosine kinase inhibitors". Oncology Letters 15, no. 1 (2018): 129-136. https://doi.org/10.3892/ol.2017.7323